Role of bile acid receptors FXR and TGR5 in preventing injury in short bowel syndrome
胆汁酸受体 FXR 和 TGR5 在预防短肠综合征损伤中的作用
基本信息
- 批准号:10491865
- 负责人:
- 金额:$ 37.88万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-09-22 至 2026-07-31
- 项目状态:未结题
- 来源:
- 关键词:AddressAgonistAnimal ModelAnimalsAtrophicAutomobile DrivingBile Acid Biosynthesis PathwayBile AcidsBlood CirculationCYP7A1 geneCathetersChenodeoxycholic AcidCholestasisCholesterol 7-alpha-MonooxygenaseComplicationDataDependenceDoseDuodenumDyslipidemiasEnteralEnteral FeedingEnteral NutritionEnterocytesEnterohepatic CirculationEtiologyExcisionFGF19 geneFailureFatty LiverFibroblast Growth Factor ReceptorsGLP-2GPBAR1 geneGene ExpressionGlucoseGlucose IntoleranceHepaticHistologyHourHumanImpairmentInflammationInjuryInsulinIntestinal permeabilityIntestinesIntravenousKnowledgeLinkLipidsLiverLiver diseasesModelingNuclear ReceptorsNutritionalOleanolic AcidOperative Surgical ProceduresPathogenesisPathway interactionsPatientsPeptide Signal SequencesPilot ProjectsPreventionProcessProteinsPublishingPumpReceptor ActivationRepressionResearchResearch PersonnelRodentRoleScheduleSerologySerumShort Bowel SyndromeSignal PathwaySignal TransductionTestingTotal Parenteral NutritionTreatment outcomebaseblood glucose regulationclinically relevantdeprivationglucagon-like peptideglucagon-like peptide 1insightintrahepaticliver injurynovelnutritionporcine modelpreventreceptorrestorationside effect
项目摘要
PROJECT SUMMARY / ABSTRACT
Bowel resection leads to the devastating condition of Short Bowel Syndrome (SBS). SBS patients cannot
maintain nutrition through regular enteral nutrition (EN) due to insufficient intestines. Such patients, in the
absence of EN, require intravenous nutrition via a process called Total Parenteral nutrition (TPN) for survival.
Worldwide, tens of thousands of patients require TPN. Despite the lifesaving TPN, side effects in SBS include
potentially fatal liver and gut injury. Although, many researchers have focused on the detrimental effects of the
constituents of TPN, results from our published studies highlight our novel hypothesis that the state of luminal
content deprivation in SBS, disrupts the normal gut derived signals and drives injury mechanisms in SBS.
Our published data shows that during EN, as part of normal enterohepatic circulation of bile acids (BA),
activation of gut Farnesoid X Receptor (FXR) by BA results in release of Fibroblast Growth Factor 19 (FGF19).
FGF19 regulates hepatic BA, cholestasis, lipid, and glucose homeostasis. Due to a lack of gut FXR activation
in SBS we hypothesize that the FXR-FGF19 signaling axis is impaired. We have also published that BA
prevent gut atrophy by enhancing Glucagon Like Peptides (GLPs). GLPs are regulated via BA activated gut
receptor TGR5. While GLP-2 is a gut trophic factor; GLP-1 modulates hepatic steatosis, insulin, and glucose.
We hypothesize that inadequate gut TGR5 activation in SBS additionally drives liver and gut injury.
Novel Model: We have established a novel untethered ambulatory SBS piglet model using miniature pumps,
jugular and duodenal catheters, and surgical bowel resection (SLU#2346,43-R-011) to closely recapitulate
human SBS. Proof of Concept: We have published that in animals on TPN without bowel resection (and not
receiving EN), treatment with gut FXR agonist, Chenodeoxycholic acid (CDCA) or gut TGR5 agonist Oleanolic
Acid (OA), as well as intravenous FGF19 and GLP-1/GLP-2 can prevent liver and gut injury. Importantly, we
have shown inadequate gut FXR and gut TGR5 activation and decreased FGF19, GLP-1/GLP-2 in SBS
animals. In pilot studies we have noted hepatic and gut protection with CDCA and OA treatment in SBS.
Thus, our central premise is to critically understand alteration in gut FXR and gut TGR5 driven signaling in
SBS and to test if its restoration in SBS animals mitigates injury. As detailed in the research plan, we will test
our hypothesis under the following aims. With Aim 1 we will critically test the roles of intravenous FGF19 and
the gut FXR agonist, CDCA on liver injury in SBS. We will analyze serum, histology, key receptors, and
transporters along the FXR-FGF19 axis to understand mechanistic links. With Aim 2 we will deliver the gut
TGR5 agonist, OA as well as GLP-1/GLP-2 in SBS animals and explore TGR5-GLP axis driven protective
mechanisms in SBS, assessing serology, histology, gut trophic factors, morphometrics and gene expression.
This project, using a highly translatable SBS model will help advance strategies to mitigate serious
complications and provide key insights into drivers of injury in SBS.
项目总结/摘要
肠切除导致短肠综合征(SBS)的破坏性条件。SBS患者不能
由于肠道不足,通过定期肠内营养(EN)维持营养。这样的病人,在
没有EN,需要通过称为全肠外营养(TPN)的过程进行静脉营养才能生存。
在世界范围内,成千上万的患者需要TPN。尽管有救命的TPN,SBS的副作用包括
可能致命的肝脏和肠道损伤虽然,许多研究人员都集中在有害影响的
TPN的成分,我们发表的研究结果强调了我们的新假设,即管腔的状态
SBS中的内容剥夺,破坏了正常的肠道来源的信号,并驱动SBS中的损伤机制。
我们发表的数据显示,在EN期间,作为胆汁酸(BA)正常肠肝循环的一部分,
BA对肠法尼醇X受体(FXR)的激活导致成纤维细胞生长因子19(FGF 19)的释放。
FGF 19调节肝BA、胆汁淤积、脂质和葡萄糖稳态。由于缺乏肠道FXR激活
在SBS中,我们假设FXR-FGF 19信号传导轴受损。我们还公布了BA
通过增强胰高血糖素样肽(GLP)预防肠道萎缩。GLP通过BA激活的肠道调节
受体TGR 5。GLP-2是一种肠道营养因子; GLP-1调节肝脂肪变性、胰岛素和葡萄糖。
我们假设SBS中肠道TGR 5活化不足还导致肝脏和肠道损伤。
新模型:我们使用微型泵建立了一种新的非拴系行走SBS仔猪模型,
颈静脉和十二指肠导管以及外科肠切除术(SLU#2346,43-R-011),以密切概括
人SBS。概念验证:我们已经发表了在没有肠切除的TPN动物中(并且没有
接受EN),用肠道FXR激动剂、鹅去氧胆酸(CDCA)或肠道TGR 5激动剂Oleurate治疗
酸(OA)以及静脉内FGF 19和GLP-1/GLP-2可以预防肝脏和肠道损伤。重要的是我们
显示SBS中肠道FXR和肠道TGR 5活化不足以及FGF 19、GLP-1/GLP-2降低
动物在初步研究中,我们注意到SBS中CDCA和OA治疗的肝脏和肠道保护作用。
因此,我们的中心前提是批判性地理解肠道FXR和肠道TGR 5驱动的信号传导的改变,
SBS并测试其在SBS动物中的恢复是否减轻损伤。正如研究计划中详细说明的那样,我们将测试
我们的假设在以下目标。在Aim 1中,我们将严格测试静脉注射FGF 19的作用,
肠道FXR激动剂CDCA对SBS肝损伤的影响。我们将分析血清,组织学,关键受体,
沿着FXR-FGF 19轴的转运蛋白,以了解机制联系。随着目标2,我们将提供肠道
TGR 5激动剂、OA以及GLP-1/GLP-2在SBS动物中的作用,并探讨TGR 5-GLP轴驱动的保护作用
SBS机制,评估血清学,组织学,肠道营养因子,形态计量学和基因表达。
该项目使用高度可翻译的SBS模型,将有助于推进缓解严重问题的战略
并发症,并提供了关键的见解,在SBS损伤的驱动程序。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Ajay K. Jain其他文献
859 BILIARY ATRESIA THROUGH TARGETED ENDOTHELIAL DESTRUCTION (BATTED) PRESENTS A NOVEL LARGE ANIMAL MODEL, RECAPITULATING HUMAN DISEASE
- DOI:
10.1016/s0016-5085(24)04045-9 - 发表时间:
2024-05-18 - 期刊:
- 影响因子:
- 作者:
Kento Kurashima;Arun Verma;Si-Min Park;Marzena Swiderska-Syn;Sree L. Kolli;David J. Gosser;Jasmine Carter;Shaurya Mehta;Austin Sims;Jeffrey Teckman;Mustafa Nazzal;John Long;Chandrashekhara Manithody;Shin Miyata;Ajay K. Jain - 通讯作者:
Ajay K. Jain
Thrombus Entrapment by a Novel Mesh-Covered Stent in ST-Segment Elevation Myocardial Infarction
- DOI:
10.1016/j.jacc.2011.01.079 - 发表时间:
2011-11-22 - 期刊:
- 影响因子:
- 作者:
Ajay K. Jain;Martin T. Rothman - 通讯作者:
Martin T. Rothman
Bacterial skin infections in cirrhotics
- DOI:
10.1016/j.jceh.2013.02.221 - 发表时间:
2013-03-01 - 期刊:
- 影响因子:
- 作者:
Mayank Jain;Ajay K. Jain;Shohini Sircar;Chandrashekhar Waghmare;Sagar Adkar - 通讯作者:
Sagar Adkar
Increased morbidity in acute viral hepatitis with glucose-6-phosphate dehydrogenase deficiency
- DOI:
10.1007/s12664-012-0226-9 - 发表时间:
2012-08-07 - 期刊:
- 影响因子:2.100
- 作者:
Ajay K. Jain;Shohini Sircar;Mayank Jain;Sagar Adkar;Chandrashekhar Waghmare;Fatema Chahwala - 通讯作者:
Fatema Chahwala
Kinetics of n-propylaminolysis of some oxime ethers in 1:1 aqueous acetonitrile
- DOI:
10.1007/bf02069217 - 发表时间:
1987-03-01 - 期刊:
- 影响因子:1.700
- 作者:
Ajay K. Jain;V. K. Velu;K. N. Sarma - 通讯作者:
K. N. Sarma
Ajay K. Jain的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Ajay K. Jain', 18)}}的其他基金
Role of intestinal microbiota in driving injury mechanisms in short bowel syndrome
肠道微生物群在驱动短肠综合征损伤机制中的作用
- 批准号:
10580044 - 财政年份:2022
- 资助金额:
$ 37.88万 - 项目类别:
Role of intestinal microbiota in driving injury mechanisms in short bowel syndrome
肠道微生物群在驱动短肠综合征损伤机制中的作用
- 批准号:
10433531 - 财政年份:2022
- 资助金额:
$ 37.88万 - 项目类别:
Role of bile acid receptors FXR and TGR5 in preventing injury in short bowel syndrome
胆汁酸受体 FXR 和 TGR5 在预防短肠综合征损伤中的作用
- 批准号:
10683281 - 财政年份:2021
- 资助金额:
$ 37.88万 - 项目类别:
Role of bile acid receptors FXR and TGR5 in preventing injury in short bowel syndrome
胆汁酸受体 FXR 和 TGR5 在预防短肠综合征损伤中的作用
- 批准号:
10343091 - 财政年份:2021
- 资助金额:
$ 37.88万 - 项目类别:
Role of gut microbiota in total parenteral nutrition associated injury
肠道微生物群在全肠外营养相关损伤中的作用
- 批准号:
9910396 - 财政年份:2019
- 资助金额:
$ 37.88万 - 项目类别:
Role of the bile acid activated receptors FXR and TGR5 in Total Parenteral Nutrition associated hepatic and gut disease
胆汁酸激活受体 FXR 和 TGR5 在全肠外营养相关肝脏和肠道疾病中的作用
- 批准号:
10390680 - 财政年份:2016
- 资助金额:
$ 37.88万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 37.88万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 37.88万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 37.88万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 37.88万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 37.88万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 37.88万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 37.88万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 37.88万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 37.88万 - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
$ 37.88万 - 项目类别:
Grant-in-Aid for Scientific Research (C)